Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula

The Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA-23-100-SOL-00004) is an ongoing government solicitation designed to support advanced research and development in medical countermeasures addressing a wide range of public health threats, including chemical, biological, radiological, nuclear (CBRN) threats, emerging infectious diseases, and other health emergencies. The BAA covers multiple areas of interest such as vaccines, antivirals, antitoxins, antimicrobials, diagnostics, burn and blast trauma treatments, and strategic therapeutics. It provides a comprehensive framework for potential offerors, including detailed proposal submission instructions, evaluation criteria, award types, and regulatory and manufacturing guidance. The solicitation emphasizes multi-stage application procedures involving initial pre-submission calls, quad chart submissions, and full proposals. Security, confidentiality, supply chain risk assessment, and reporting requirements are integral components of the process, ensuring alignment with current scientific, regulatory, and national security standards. Since the initial release in September 2023, the BAA has undergone multiple amendments updating and refining Areas of Interest (AOIs), proposal guidelines, evaluation criteria, and technology readiness level requirements. Some AOIs have been suspended or deleted, such as certain COVID-19 immune assays and needle-free vaccine technologies, reflecting evolving program priorities. Recent amendments have introduced new technical attachments, enhanced supply chain scrutiny, and expanded or adjusted focus areas to adapt to emerging scientific challenges. The final proposal submission deadline for open areas of interest is September 25, 2028. Contracting inquiries are managed centrally via BARDA-BAA@hhs.gov. This solicitation represents a critical funding and partnership opportunity for organizations engaged in innovative biomedical research to bolster national preparedness and response capabilities.